Maryland State Retirement & Pension System Has $355,000 Stock Position in Artivion, Inc. (NYSE:AORT)

Maryland State Retirement & Pension System lessened its position in shares of Artivion, Inc. (NYSE:AORT) by 3.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,823 shares of the company’s stock after selling 538 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Artivion were worth $355,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Artivion by 25.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock worth $186,000 after purchasing an additional 2,108 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Artivion by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 326,085 shares of the company’s stock worth $5,830,000 after buying an additional 8,090 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Artivion by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock valued at $30,156,000 after buying an additional 80,214 shares during the period. Wasatch Advisors LP boosted its stake in Artivion by 0.4% in the fourth quarter. Wasatch Advisors LP now owns 519,019 shares of the company’s stock valued at $9,280,000 after acquiring an additional 2,287 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after acquiring an additional 505 shares during the period. Institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

AORT has been the topic of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Artivion in a research note on Friday, August 9th. Oppenheimer increased their target price on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Lake Street Capital boosted their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus increased their price target on shares of Artivion from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

Insider Buying and Selling at Artivion

In other news, Director Anthony B. Semedo sold 9,709 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares of the company’s stock, valued at approximately $863,475.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the transaction, the director now directly owns 34,159 shares of the company’s stock, valued at $853,633.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,679 shares of company stock valued at $626,518. 8.10% of the stock is currently owned by corporate insiders.

Artivion Stock Performance

Shares of Artivion stock opened at $26.19 on Wednesday. The stock’s fifty day simple moving average is $26.21 and its 200 day simple moving average is $23.19. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $1.09 billion, a PE ratio of -109.13 and a beta of 1.75. Artivion, Inc. has a 12 month low of $12.16 and a 12 month high of $29.24.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The company had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. On average, research analysts predict that Artivion, Inc. will post 0.2 EPS for the current year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.